Qiagen (QGEN) AI Stock Analysis

• Market Cap: $10.10B
• Dividend Yield: 3.31%
• Average Volume (3M): 2.87M
• Price to Earnings (P/E): 24.4
• Beta (1Y): 0.58
• Revenue Growth: 5.32%
• EPS Growth: 336.29%
• Country: US
• Employees: 5,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.62
• Shares Outstanding: 206,800,000
• 10 Day Avg. Volume: 1,499,727
• 30 Day Avg. Volume: 2,865,979
• PEG Ratio: 0.05
• Price to Book (P/B): 2.61
• Price to Sales (P/S): 4.71
• P/FCF Ratio: 21.72
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 5.20
• Enterprise Value/Gross Profit: 8.42
• Enterprise Value/Ebitda: 15.16
• 1Y Price Target: $55.37
• Price Target Upside: 11.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): 2.52
• Revenue Forecast (FY): $2.22B

• Rating: 72 Outperform
• Price Target: $57.00 ▲(14.46% Upside)
• Action: Reiterated Date: 02/07/26
• Date: Action: Reiterated 02/07/26

The score is driven primarily by improved 2025 financial performance and a supportive outlook for continued profitable growth in 2026, tempered by historical earnings/cash-flow variability and near-term operational headwinds. Technicals are constructive but not strongly bullish, while valuation is helped by the high dividend yield despite a mid-range P/E.

Positive Factors

High Profitability and Margins

Sustained high gross and net margins indicate strong pricing power and efficient operations across consumables and assays. Durable margin structure supports reinvestment in R&D, funds shareholder returns, and provides a buffer against cyclical revenue swings over the medium term.

Strengthening Product Portfolio & Growth Areas

Consistent growth in diagnostics and digital PCR, plus the Parse Biosciences acquisition, expands exposure to high-growth single-cell and AI-driven genomics. This diversifies revenue toward structural, consumable-heavy markets with recurring demand and higher long-term TAM.

Manageable Leverage and Capital Structure

Moderate leverage and solid ROE provide financial flexibility for M&A, R&D funding, and shareholder returns without overburdening cash flow. A healthy capital structure supports strategic investments and resilience through industry cycles over the next several quarters.

Negative Factors

Slowing Revenue and Declining Free Cash Flow

Slowing top-line momentum and negative FCF growth erode internal funding for innovation and could increase reliance on buybacks to sustain EPS. If persistent, this weakens the company’s ability to fund organic expansion and meet its 7% multi-year growth ambitions.

Regional Exposure: Asia Pacific / China Weakness

A mid‑teen decline in China represents a meaningful loss in a large growth market and signals execution or demand issues. Prolonged weakness in APAC could materially slow consolidated growth and necessitate targeted commercial or regulatory strategies to restore momentum.

Currency and Tariff Headwinds

Persistent FX volatility and tariff exposure can structurally compress margins and force pricing or cost adjustments. Over months, these pressures complicate margin guidance and may require sustainable cost or supply-chain changes that affect competitiveness and profitability.

Qiagen Business Overview & Revenue Model

Company Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

How the Company Makes Money

Qiagen generates revenue primarily through the sale of its products and services across several key segments. The company's revenue model is based on the sale of consumables, instruments, and services, with consumables being the largest revenue contributor, driven by the ongoing demand for molecular testing and personalized medicine. Key revenue streams include the sale of sample preparation kits and molecular assays for use in research and clinical settings. Additionally, Qiagen benefits from strategic partnerships with healthcare providers, pharmaceutical companies, and research institutions, which enhance its market reach and allow for collaborative product development. The growing trend towards precision medicine and increased investment in genomic research further support Qiagen's earnings potential.

Qiagen Financial Statement Overview

Summary

Financials show a meaningful 2025 rebound with strong profitability (net margin ~20%, operating margin ~25%) and improved gross margin (~62%). Leverage is manageable (debt-to-equity ~0.44) and cash generation is solid (2025 OCF ~$654M, FCF ~$453M), but multi-year volatility (notably the 2024 dip) and uneven cash conversion/FCF trend keep the score below top-tier.

Income Statement

Profitability is strong and has rebounded meaningfully: 2025 revenue rose to ~$2.09B (about +6% vs. 2024) while net margin expanded sharply to ~20% (vs. ~4% in 2024), with operating margin back near ~25% (vs. ~8% in 2024). Gross margin also improved to ~62% in 2025 from ~49% in 2024, closer to the company’s historically higher levels (2020–2023). The key weakness is volatility in earnings power and margins across years (notably the 2024 dip), and reported revenue growth appears inconsistent over time (including down years).

Balance Sheet

Leverage looks manageable: debt-to-equity sits around ~0.44 in 2025 (improved from ~0.54 in 2022 and ~0.63–0.70 in 2020–2021), supported by a sizable equity base (~$3.78B) against ~$1.65B of debt. Returns on equity improved to ~11% in 2025 after a weak 2024 (~2%), indicating better profitability on the capital base. The main watch items are the upward move in absolute debt from 2024 to 2025 and the historical variability in returns, which can pressure balance-sheet flexibility if performance softens again.

Cash Flow

Cash generation is solid, with 2025 operating cash flow of ~$654M and free cash flow of ~$453M, and operating cash flow exceeding net income (coverage ~1.28x), supporting earnings quality. Free cash flow also covers a meaningful share of profits (about ~69% of net income in 2025). Offsetting this, free cash flow declined in 2025 (negative growth vs. 2024) and cash conversion has been uneven historically (including a notably weak operating cash flow coverage in 2021–2023), suggesting potential working-capital or investment-driven volatility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.09B	1.98B	1.97B	2.14B	2.25B
Gross Profit	1.29B	967.35M	1.23B	1.38B	1.45B
EBITDA	717.27M	368.26M	688.55M	779.36M	895.24M
Net Income	424.88M	83.59M	341.30M	423.21M	512.60M
Balance Sheet
Total Assets	6.30B	5.69B	6.12B	6.29B	6.15B
Cash, Cash Equivalents and Short-Term Investments	1.10B	1.15B	1.06B	1.42B	1.07B
Total Debt	1.65B	1.61B	1.69B	2.03B	2.12B
Total Liabilities	2.52B	2.12B	2.31B	2.82B	3.05B
Stockholders Equity	3.78B	3.57B	3.81B	3.47B	3.10B
Cash Flow
Free Cash Flow	453.28M	506.38M	296.65M	565.93M	432.47M
Operating Cash Flow	654.33M	673.55M	459.45M	715.26M	639.00M
Investing Cash Flow	-305.28M	-249.23M	-87.66M	-726.76M	-202.43M
Financing Cash Flow	-178.98M	-422.90M	-433.83M	-125.80M	-150.37M

Qiagen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 49.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Positive. The current price of 49.8 is below the 20-day moving average (MA) of 50.20, above the 50-day MA of 49.24, and above the 200-day MA of 47.41, indicating a neutral trend. The MACD of -0.43 indicates Positive momentum. The RSI at 50.04 is Neutral, neither overbought nor oversold. The STOCH value of 52.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QGEN.

Qiagen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	72 Outperform	$10.10B	24.37	11.57%	3.31%	5.32%	336.29%
IDXX	70 Outperform	$50.70B	48.68	66.20%	―	8.39%	21.44%
RVTY	64 Neutral	$10.69B	47.36	3.22%	0.29%	3.37%	-18.80%
TMO	61 Neutral	$188.93B	29.38	13.02%	0.30%	3.91%	7.09%
ILMN	59 Neutral	$20.32B	24.32	33.36%	―	-2.39%	―
IQV	59 Neutral	$29.57B	22.18	21.64%	―	3.85%	-4.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Qiagen Corporate Events

Qiagen Tops 2025 Guidance and Sets Ambitious 2026 Growth Targets

On February 4, 2026, Qiagen reported unaudited results for the fourth quarter and full year ended December 31, 2025, posting Q4 net sales of $540 million, up 4% year on year (1% at constant exchange rates), and diluted EPS of $0.49, with adjusted diluted EPS of $0.62 at constant exchange rates beating its guidance. For 2025, net sales rose 6% to $2.09 billion (5% at constant exchange rates), at the top end of its upgraded outlook, while adjusted diluted EPS reached $2.40 at constant exchange rates, ahead of forecasts, underpinned by 8% constant-currency growth in its strategic growth pillars to $1.49 billion, an 80-basis-point improvement in adjusted operating margin to 29.5% despite tariffs and FX headwinds, and the first contribution from the Parse acquisition alongside headwinds from discontinued NeuMoDx and Dialunox products. Management highlighted disciplined execution in a challenging macro environment, including the impact of the 2025 U.S. government shutdown, continued cost-efficiency and digitization efforts, and an accelerated capital allocation program that returned more than $1.1 billion to shareholders and added Genoox and Parse as bolt-on deals, while setting a 2026 outlook for at least 5% constant-currency sales growth driven by roughly 9% growth in its core pillars and adjusted EPS of at least $2.50, signaling confidence in sustained profitable expansion and ongoing investment capacity.

The most recent analyst rating on (QGEN) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.